## References

[1.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref1-1 "View in article")

Sung, H. ∙ Ferlay, J. ∙ Siegel, R.L. ...

**Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries**

*CA Cancer J Clin.* 2021; **71**:209-249

[Crossref](https://doi.org/10.3322/caac.21660)

[Scopus (43233)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_1_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85100345654)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33538338/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.3322%2Fcaac.21660&pmid=33538338)

[2.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref2 "View in article")

Anderson, W.F. ∙ Jatoi, I. ∙ Tse, J. ...

**Male breast cancer: a population-based comparison with female breast cancer**

*J Clin Oncol.* 2010; **28**:232-239

[Crossref](https://doi.org/10.1200/JCO.2009.23.8162)

[Scopus (325)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_2_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-74949102413)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/19996029/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2009.23.8162&pmid=19996029)

[3.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref3 "View in article")

Heer, E. ∙ Harper, A. ∙ Escandor, N. ...

**Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study**

*Lancet Glob Health.* 2020; **8**:e1027-e1037

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_3_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS2214-109X%2820%2930215-1&cf=fulltext&site=lancet-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_3_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS2214-109X%2820%2930215-1&cf=pdf&site=lancet-site)

[Scopus (343)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_3_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85088143648)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/32710860/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2FS2214-109X%2820%2930215-1&pmid=32710860)

[4.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref4-1 "View in article")

Xu, S. ∙ Liu, Y. ∙ Zhang, T. ...

**The global, regional, and national burden and trends of breast cancer from 1990 to 2019: results from the Global Burden of Disease Study 2019**

*Front Oncol.* 2021; **11**, 689562

[Google Scholar](https://scholar.google.com/scholar?q=S.XuY.LiuT.ZhangThe+global%2C+regional%2C+and+national+burden+and+trends+of+breast+cancer+from+1990+to+2019%3A+results+from+the+Global+Burden+of+Disease+Study+2019Front+Oncol112021689562)

[5.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref5 "View in article")

Youn, H.J. ∙ Han, W.

**A review of the epidemiology of breast cancer in Asia: focus on risk factors**

*Asian Pac J Cancer Prev.* 2020; **21**:867-880

[Crossref](https://doi.org/10.31557/APJCP.2020.21.4.867)

[Scopus (51)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_5_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85084030308)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/32334446/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.31557%2FAPJCP.2020.21.4.867&pmid=32334446)

[6.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref6 "View in article")

Ginsburg, O. ∙ Bray, F. ∙ Coleman, M.P. ...

**The global burden of women's cancers: a grand challenge in global health**

*Lancet.* 2017; **389**:847-860

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_6_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS0140-6736%2816%2931392-7&cf=fulltext&site=lancet-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_6_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS0140-6736%2816%2931392-7&cf=pdf&site=lancet-site)

[Scopus (608)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_6_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85005916238)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/27814965/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0140-6736%2816%2931392-7&pmid=27814965)

[7.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref7 "View in article")

Malvia, S. ∙ Bagadi, S.A. ∙ Dubey, U.S. ...

**Epidemiology of breast cancer in Indian women**

*Asia Pac J Clin Oncol.* 2017; **13**:289-295

[Crossref](https://doi.org/10.1111/ajco.12661)

[Scopus (347)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_7_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85011949683)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/28181405/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1111%2Fajco.12661&pmid=28181405)

[8.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref8 "View in article")

**Japanese cancer statistics by stage**

Available at

[https://www.zengankyo.ncc.go.jp/etc/seizonritsu/seizonritsu2013.html](https://www.zengankyo.ncc.go.jp/etc/seizonritsu/seizonritsu2013.html)

Date accessed: August 30, 2022

[Google Scholar](https://scholar.google.com/scholar?q=Japanese+cancer+statistics+by+stageAvailable+athttps%3A%2F%2Fwww.zengankyo.ncc.go.jp%2Fetc%2Fseizonritsu%2Fseizonritsu2013.html)

[9.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref9 "View in article")

Kang, S.Y. ∙ Lee, S.B. ∙ Kim, Y.S. ...

**Breast cancer statistics in Korea, 2018**

*J Breast Cancer.* 2021; **24**:123-137

[Crossref](https://doi.org/10.4048/jbc.2021.24.e22)

[Scopus (24)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_9_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85105602216)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33913273/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.4048%2Fjbc.2021.24.e22&pmid=33913273)

[10.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref10 "View in article")

Bhoo-Pathy, N. ∙ Verkooijen, H.M. ∙ Tan, E.Y. ...

**Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting**

*Sci Rep.* 2015; **5**, 16252

[Crossref](https://doi.org/10.1038/srep16252)

[Scopus (17)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_10_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-84946599591)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1038%2Fsrep16252)

[11.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref11 "View in article")

Bhoo Pathy, N. ∙ Yip, C.H. ∙ Taib, N.A. ...

**Breast cancer in multi-ethnic Asian setting: results from Singapore-Malaysia hospital based breast cancer registry**

*Breast.* 2011; **20**:S75-S80

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_11_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.breast.2011.01.015&cf=fulltext&site=ybrst-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_11_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.breast.2011.01.015&cf=pdf&site=ybrst-site)

[Scopus (0)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_11_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-79953063689)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.breast.2011.01.015)

[12.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref12-1 "View in article")

Lin, C.H. ∙ Yap, Y.S. ∙ Lee, K.H. ...

**Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population**

*J Natl Cancer Inst.* 2019; **111**:1298-1306

[Crossref](https://doi.org/10.1093/jnci/djz090)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31093668/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1093%2Fjnci%2Fdjz090&pmid=31093668)

[13.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref13-1 "View in article")

Yap, Y.-S. ∙ Lu, Y.-S. ∙ Tamura, K. ...

**Insights into breast cancer in the east versus the west: a review**

*JAMA Oncol.* 2019; **5**:1489-1496

[Crossref](https://doi.org/10.1001/jamaoncol.2019.0620)

[Scopus (60)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_13_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85065802784)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31095268/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1001%2Fjamaoncol.2019.0620&pmid=31095268)

[14.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref14 "View in article")

Hirko, K.A. ∙ Rocque, G. ∙ Reasor, E. ...

**The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology**

*BMC Med.* 2022; **20**:72

[Crossref](https://doi.org/10.1186/s12916-022-02260-0)

[Scopus (11)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_14_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85124590613)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/35151316/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1186%2Fs12916-022-02260-0&pmid=35151316)

[15.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref15-1 "View in article")

Szostakowska, M. ∙ Trebinska-Stryjewska, A. ∙ Grybowska, E. ...

**Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals**

*Breast Cancer Res Treat.* 2019; **173**:489-497

[Crossref](https://doi.org/10.1007/s10549-018-5023-4)

[Scopus (98)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_15_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85055961038)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/30382472/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1007%2Fs10549-018-5023-4&pmid=30382472)

[16.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref16 "View in article")

Shimoi, T. ∙ Nagai, S.E. ∙ Yoshinami, T. ...

**The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition**

*Breast Cancer.* 2020; **27**:322-331

[Crossref](https://doi.org/10.1007/s12282-020-01085-0)

[Scopus (27)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_16_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85082927230)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/32240526/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1007%2Fs12282-020-01085-0&pmid=32240526)

[17.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref17 "View in article")

Uematsu, T. ∙ Nakashima, K. ∙ Kikuchi, M. ...

**The Japanese Breast Cancer Society Clinical Practice Guidelines for breast cancer screening and diagnosis, 2018 edition**

*Breast Cancer.* 2020; **27**:17-24

[Crossref](https://doi.org/10.1007/s12282-019-01025-7)

[Scopus (9)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_17_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85077681154)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31734900/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1007%2Fs12282-019-01025-7&pmid=31734900)

[18.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref18 "View in article")

Yeo, W. ∙ Ueno, T. ∙ Lin, C.H. ...

**Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression**

*Breast Cancer Res Treat.* 2019; **177**:549-559

[Crossref](https://doi.org/10.1007/s10549-019-05318-5)

[Scopus (28)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_18_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85068851765)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31270763/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1007%2Fs10549-019-05318-5&pmid=31270763)

[19.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref19 "View in article")

Rangarao, R. ∙ Smruti, B.K. ∙ Singh, K. ...

**Practical consensus recommendations on management of triple-negative metastatic breast cancer**

*South Asian J Cancer.* 2018; **7**:127-131

[Crossref](https://doi.org/10.4103/sajc.sajc_118_18)

[Scopus (2)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_19_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85097392939)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/29721479/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.4103%2Fsajc.sajc_118_18&pmid=29721479)

[20.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref20 "View in article")

**Korean Breast Cancer Society. The 9th Korean Clinical Practice Guideline for breast cancer 2021**

Available at

[https://www.kbcs.or.kr/journal/file/211104_211102.pdf](https://www.kbcs.or.kr/journal/file/211104_211102.pdf)

Date accessed: May 3, 2023

[Google Scholar](https://scholar.google.com/scholar?q=Korean+Breast+Cancer+Society.+The+9th+Korean+Clinical+Practice+Guideline+for+breast+cancer+2021Available+athttps%3A%2F%2Fwww.kbcs.or.kr%2Fjournal%2Ffile%2F211104_211102.pdf)

[21.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref21-1 "View in article")

Gennari, A. ∙ Andre, F. ∙ Barrios, C.H. ...

**ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer**

*Ann Oncol.* 2021; **32**:1475-1495

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_21_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2021.09.019&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_21_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2021.09.019&cf=pdf&site=annonc-site)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/34678411/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.annonc.2021.09.019&pmid=34678411)

[22.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref22 "View in article")

**Dykewicz CA, Centers for Disease Control and Prevention. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients**

*Clin Infect Dis.* 2001; **33**:139-144

[Crossref](https://doi.org/10.1086/321805)

[Scopus (0)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_22_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-0035879607)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/11418871/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1086%2F321805&pmid=11418871)

[23.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref23-1 "View in article")

Modi, S. ∙ Jascot, W. ∙ Yamashita, T. ...

**Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04, a randomized, phase 3 study**

*J Clin Oncol.* 2022; **40** LBA3

[Crossref](https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA3)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2022.40.17_suppl.LBA3)

[24.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref24-1 "View in article")

[https://www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/2018-her2-testing-algorithms.pdf](https://www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/2018-her2-testing-algorithms.pdf)

Date accessed: May 3, 2023

[Google Scholar](https://scholar.google.com/scholar?q=https%3A%2F%2Fwww.asco.org%2Fsites%2Fnew-www.asco.org%2Ffiles%2Fcontent-files%2Fpractice-and-guidelines%2Fdocuments%2F2018-her2-testing-algorithms.pdf)

[25.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref25-1 "View in article")

Wolff, A.C. ∙ Hammond, M.E.H. ∙ Allison, K.H. ...

**Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update**

*J Clin Oncol.* 2018; **36**:2105-2122

[Crossref](https://doi.org/10.1200/JCO.2018.77.8738)

[Scopus (1142)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_25_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85049596746)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/29846122/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2018.77.8738&pmid=29846122)

[26.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref26-1 "View in article")

Cardoso, F. ∙ Paluch-Shimon, S. ∙ Senkus, E. ...

**5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)**

*Ann Oncol.* 2020; **31**:1623-1649

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_26_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2020.09.010&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_26_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2020.09.010&cf=pdf&site=annonc-site)

[Scopus (652)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_26_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85094163853)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/32979513/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.annonc.2020.09.010&pmid=32979513)

[27.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref27-1 "View in article")

Lee, C.I. ∙ Gold, L.S. ∙ Nelson, H.D. ...

**Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response**

*Breast.* 2015; **24**:3-11

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_27_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.breast.2014.11.009&cf=fulltext&site=ybrst-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_27_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.breast.2014.11.009&cf=pdf&site=ybrst-site)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/25479913/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.breast.2014.11.009&pmid=25479913)

[28.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref28 "View in article")

Accordino, M.K. ∙ Wright, J.D. ∙ Vasan, S. ...

**Use and costs of disease monitoring in women with metastatic breast cancer**

*J Clin Oncol.* 2016; **34**:2820-2826

[Crossref](https://doi.org/10.1200/JCO.2016.66.6313)

[Scopus (29)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_28_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-84982121586)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/27161970/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2016.66.6313&pmid=27161970)

[29.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref29 "View in article")

Kosmin, M. ∙ Padhani, A.R. ∙ Gogbashian, A. ...

**Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone**

*Radiology.* 2020; **297**:622-629

[Crossref](https://doi.org/10.1148/radiol.2020192683)

[Scopus (23)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_29_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85096347642)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33078998/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1148%2Fradiol.2020192683&pmid=33078998)

[30.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref30 "View in article")

Fourney, D.R. ∙ Frangou, E.M. ∙ Ryken, T.C. ...

**Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group**

*J Clin Oncol.* 2011; **29**:3072-3077

[Crossref](https://doi.org/10.1200/JCO.2010.34.3897)

[Scopus (397)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_30_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-80051662170)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/21709187/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2010.34.3897&pmid=21709187)

[31.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref31 "View in article")

Komorowski, A.S. ∙ Warner, E. ∙ MacKay, H.J. ...

**Incidence of brain metastases in nonmetastatic and metastatic breast cancer: is there a role for screening?**

*Clin Breast Cancer.* 2020; **20**:e54-e64

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_31_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.clbc.2019.06.007&cf=fulltext&site=clbc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_31_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.clbc.2019.06.007&cf=pdf&site=clbc-site)

[Scopus (0)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_31_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85071136687)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31447286/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.clbc.2019.06.007&pmid=31447286)

[32.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref32 "View in article")

DeSantis, C.E. ∙ Ma, J. ∙ Gaudet, M.M. ...

**Breast cancer statistics, 2019**

*CA Cancer J Clin.* 2019; **69**:438-451

[Crossref](https://doi.org/10.3322/caac.21583)

[Scopus (1904)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_32_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85073960571)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31577379/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.3322%2Fcaac.21583&pmid=31577379)

[33.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref35 "View in article")

Goetz, M.P. ∙ Toi, M. ∙ Campone, M. ...

**MONARCH 3: abemaciclib as initial therapy for advanced breast cancer**

*J Clin Oncol.* 2017; **35**:3638-3646

[Crossref](https://doi.org/10.1200/JCO.2017.75.6155)

[Scopus (988)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_33_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85032984371)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/28968163/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2017.75.6155&pmid=28968163)

[34.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref35 "View in article")

Johnston, S. ∙ Martin, M. ∙ Di Leo, A. ...

**MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer**

*NPJ Breast Cancer.* 2019; **5**:5

[Crossref](https://doi.org/10.1038/s41523-018-0097-z)

[Scopus (308)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_34_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85063207699)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/30675515/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41523-018-0097-z&pmid=30675515)

[35.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref35 "View in article")

Johnston, S. ∙ O’Shaughnessy, J. ∙ Martin, M. ...

**Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups**

*NPJ Breast Cancer.* 2021; **7**:80

[Crossref](https://doi.org/10.1038/s41523-021-00289-7)

[Scopus (24)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_35_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85108336793)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/34158513/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41523-021-00289-7&pmid=34158513)

[36.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref36-1 "View in article")

Finn, R.S. ∙ Rugo, H.S. ∙ Dieras, V.C. ...

**Overall survival (OS) with first-line palbociclib plus letrozole (PAL + LET) versus palcebo plus letrozole (PBO + LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2- ABC): analyses from PALOMA-2**

*J Clin Oncol.* 2022; **40**:LBA1003

[Google Scholar](https://scholar.google.com/scholar?q=R.S.FinnH.S.RugoV.C.DierasOverall+survival+%28OS%29+with+first-line+palbociclib+plus+letrozole+%28PAL%C2%A0%2B+LET%29+versus+palcebo+plus+letrozole+%28PBO%C2%A0%2B+LET%29+in+women+with+estrogen+receptor-positive%2Fhuman+epidermal+growth+factor+receptor+2-negative+advanced+breast+cancer+%28ER%2B%2FHER2-+ABC%29%3A+analyses+from+PALOMA-2J%C2%A0Clin+Oncol402022LBA1003)

[37.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref37 "View in article")

Im, S.A. ∙ Mukai, H. ∙ Park, I.H. ...

**Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study**

*J Glob Oncol.* 2019; **5**:1-19

[Google Scholar](https://scholar.google.com/scholar?q=S.A.ImH.MukaiI.H.ParkPalbociclib+plus+letrozole+as+first-line+therapy+in+postmenopausal+Asian+women+with+metastatic+breast+cancer%3A+results+from+the+phase+III%2C+randomized+PALOMA-2+studyJ%C2%A0Glob+Oncol52019119)

[38.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref38-1 "View in article")

Hortobagyi, G.N. ∙ Stemmer, S.M. ∙ Burris, H.A. ...

**Ribociclib as first-line therapy for HR-positive, advanced breast cancer**

*N Engl J Med.* 2016; **375**:1738-1748

[Crossref](https://doi.org/10.1056/NEJMoa1609709)

[Scopus (1239)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_38_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-84994151988)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/27717303/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1609709&pmid=27717303)

[39.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref39-1 "View in article")

Hortobagyi, G.N. ∙ Stemmer, S.M. ∙ Burris, H.A. ...

**Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer**

*Ann Oncol.* 2018; **29**:1541-1547

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_39_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1093%2Fannonc%2Fmdy155&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_39_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1093%2Fannonc%2Fmdy155&cf=pdf&site=annonc-site)

[Scopus (453)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_39_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85050821270)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/29718092/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1093%2Fannonc%2Fmdy155&pmid=29718092)

[40.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref42-1 "View in article")

Im, S.A. ∙ Lu, Y.S. ∙ Bardia, A. ...

**Overall survival with ribociclib plus endocrine therapy in breast cancer**

*N Engl J Med.* 2019; **381**:307-316

[Crossref](https://doi.org/10.1056/NEJMoa1903765)

[Scopus (574)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_40_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85068361995)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31166679/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1903765&pmid=31166679)

[41.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref42-1 "View in article")

Lu, Y.-S. ∙ Im, S.A. ∙ Colleoni, M. ...

**Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial**

*Clin Cancer Res.* 2022; **28**:851-859

[Crossref](https://doi.org/10.1158/1078-0432.CCR-21-3032)

[Scopus (55)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_41_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85125729661)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/34965945/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1158%2F1078-0432.CCR-21-3032&pmid=34965945)

[42.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref42-1 "View in article")

Tripathy, D. ∙ Im, S.A. ∙ Colleoni, M. ...

**Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial**

*Lancet Oncol.* 2018; **19**:904-915

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_42_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2818%2930292-4&cf=fulltext&site=lancet-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_42_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2818%2930292-4&cf=pdf&site=lancet-site)

[Scopus (579)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_42_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85047257394)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/29804902/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2818%2930292-4&pmid=29804902)

[43.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref43-1 "View in article")

Lee, K.W.C. ∙ Lord, S. ∙ Finn, R.S. ...

**The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis**

*Breast Cancer Res Treat.* 2019; **174**:271-278

[Crossref](https://doi.org/10.1007/s10549-018-5054-x)

[Scopus (22)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_43_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85056886571)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/30465154/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1007%2Fs10549-018-5054-x&pmid=30465154)

[44.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref44-1 "View in article")

Im, S.A. ∙ Yap, Y.S. ∙ Sohn, J. ...

**Pooled analysis of efficacy and safety in Asian patients (pts) in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials of ribociclib (RIB) plus endocrine therapy (ET)**

*Ann Oncol.* 2019; **30**:ix15 abstr 390

[Google Scholar](https://scholar.google.com/scholar?q=S.A.ImY.S.YapJ.SohnPooled+analysis+of+efficacy+and+safety+in+Asian+patients+%28pts%29+in+the+MONALEESA-2%2C+MONALEESA-3%2C+and+MONALEESA-7+trials+of+ribociclib+%28RIB%29+plus+endocrine+therapy+%28ET%29Ann+Oncol302019ix15abstr+390)

[45.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref45-1 "View in article")

Sledge, Jr., G.W. ∙ Toi, M. ∙ Neven, P. ...

**MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy**

*J Clin Oncol.* 2017; **35**:2875-2884

[Crossref](https://doi.org/10.1200/JCO.2017.73.7585)

[Scopus (1020)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_45_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85027966887)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/28580882/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2017.73.7585&pmid=28580882)

[46.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref46-1 "View in article")

Iwata, H. ∙ Im, S.A. ∙ Masuda, N. ...

**PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients**

*J Glob Oncol.* 2017; **3**:289-303

[PubMed](https://pubmed.ncbi.nlm.nih.gov/28831437/)

[Google Scholar](https://scholar.google.com/scholar_lookup?pmid=28831437)

[47.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref47-1 "View in article")

Cristofanilli, M. ∙ Turner, N.C. ∙ Bondarenko, I. ...

**Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial**

*Lancet Oncol.* 2016; **17**:425-439

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_47_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2815%2900613-0&cf=fulltext&site=lancet-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_47_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2815%2900613-0&cf=pdf&site=lancet-site)

[Scopus (1232)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_47_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-84959316268)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/26947331/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2815%2900613-0&pmid=26947331)

[48.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref48 "View in article")

Slamon, D.J. ∙ Neven, P. ∙ Chia, S. ...

**Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3**

*J Clin Oncol.* 2018; **36**:2465-2472

[Crossref](https://doi.org/10.1200/JCO.2018.78.9909)

[Scopus (650)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_48_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85050815779)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/29860922/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2018.78.9909&pmid=29860922)

[49.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref52-1 "View in article")

Goetz, M.P. ∙ Toi, M. ∙ Huober, J. ...

**MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)**

*Ann Oncol.* 2022; **33** LBA 15

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_49_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2022.08.009&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_49_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2022.08.009&cf=pdf&site=annonc-site)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/35012799/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.annonc.2022.08.009&pmid=35012799)

[50.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref52-1 "View in article")

Inoue, K. ∙ Masuda, N. ∙ Iwata, H. ...

**Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy**

*Breast Cancer.* 2021; **28**:1038-1050

[Crossref](https://doi.org/10.1007/s12282-021-01239-8)

[Scopus (6)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_50_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85103399365)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33797023/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1007%2Fs12282-021-01239-8&pmid=33797023)

[51.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref52-1 "View in article")

Toi, M. ∙ Inoue, K. ∙ Masuda, N. ...

**Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials**

*Cancer Sci.* 2021; **112**:2381-2392

[Crossref](https://doi.org/10.1111/cas.14877)

[Scopus (6)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_51_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85104102846)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33686753/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1111%2Fcas.14877&pmid=33686753)

[52.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref52-1 "View in article")

Turner, N.C. ∙ Slamon, D.J. ∙ Ro, J. ...

**Overall survival with palbociclib and fulvestrant in advanced breast cancer**

*N Engl J Med.* 2018; **379**:1926-1936

[Crossref](https://doi.org/10.1056/NEJMoa1810527)

[Scopus (725)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_52_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85056167513)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/30345905/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1810527&pmid=30345905)

[53.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref53 "View in article")

Sledge, G.W. ∙ Toi, M. ∙ Neven, P. ...

**The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial**

*JAMA Oncol.* 2020; **6**:116-124

[Crossref](https://doi.org/10.1001/jamaoncol.2019.4782)

[Scopus (520)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_53_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85072756648)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31563959/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1001%2Fjamaoncol.2019.4782&pmid=31563959)

[54.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref54-1 "View in article")

Slamon, D.J. ∙ Neven, P. ∙ Chia, S. ...

**Overall survival with ribociclib plus fulvestrant in advanced breast cancer**

*N Engl J Med.* 2020; **382**:514-524

[Crossref](https://doi.org/10.1056/NEJMoa1911149)

[Scopus (425)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_54_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85079075053)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31826360/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1911149&pmid=31826360)

[55.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref55-1 "View in article")

Hortobagyi, G.N. ∙ Stemmer, S.M. ∙ Burris, H.A. ...

**Overall survival with ribociclib plus letrozole in advanced breast cancer**

*N Engl J Med.* 2022; **386**:942-950

[Crossref](https://doi.org/10.1056/NEJMoa2114663)

[Scopus (149)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_55_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85126081055)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/35263519/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa2114663&pmid=35263519)

[56.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref56-1 "View in article")

Park, Y.H. ∙ Kim, T.Y. ∙ Kim, G.M. ...

**Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial**

*Lancet Oncol.* 2019; **20**:1750-1759

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_56_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2819%2930565-0&cf=fulltext&site=lancet-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_56_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2819%2930565-0&cf=pdf&site=lancet-site)

[Scopus (77)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_56_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85075681308)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31668850/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2819%2930565-0&pmid=31668850)

[57.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref57 "View in article")

Giuliano, M. ∙ Schettini, F. ∙ Rognoni, C. ...

**Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis**

*Lancet.* 2019; **20**:1360-1369

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_57_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2819%2930420-6&cf=fulltext&site=lancet-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_57_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2819%2930420-6&cf=pdf&site=lancet-site)

[Scopus (91)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_57_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85072661267)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2819%2930420-6)

[58.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref58 "View in article")

Lu YS, Mahidin E, Azim H, et al. Primary results from the randomized phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy. Paper presented at SABCS 2022. December 6-10, 2022. Abstract GS1-10.

[Google Scholar](https://scholar.google.com/scholar?q=Lu+YS%2C+Mahidin+E%2C+Azim+H%2C+et%C2%A0al.+Primary+results+from+the+randomized+phase+II+RIGHT+Choice+trial+of+premenopausal+patients+with+aggressive+HR%2B%2FHER2%E2%88%92+advanced+breast+cancer+treated+with+ribociclib%C2%A0%2B+endocrine+therapy+vs+physician%E2%80%99s+choice+combination+chemotherapy.+Paper+presented+at+SABCS+2022.+December+6-10%2C+2022.+Abstract+GS1-10.)

[59.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref59-1 "View in article")

Klijn, J.G. ∙ Beex, L.V. ∙ Mauriac, L. ...

**Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study**

*J Natl Cancer Inst.* 2000; **92**:903-911

[Crossref](https://doi.org/10.1093/jnci/92.11.903)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/10841825/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1093%2Fjnci%2F92.11.903&pmid=10841825)

[60.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref60 "View in article")

Kalinsky, K. ∙ Accordino, M.K. ∙ Chiuzan, C. ...

**A randomized phase II trail of fulvestrant or examestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor-positive (HR+), HER2-neagtive metastatic breast cancer (MBC): MAINTAIN trial**

*J Clin Oncol.* 2022; **40** LBA 1004

[Google Scholar](https://scholar.google.com/scholar?q=K.KalinskyM.K.AccordinoC.ChiuzanA%C2%A0randomized+phase+II+trail+of+fulvestrant+or+examestane+with+or+without+ribociclib+after+progression+on+anti-estrogen+therapy+plus+cyclin-dependent+kinase+4%2F6+inhibition+%28CDK+4%2F6i%29+in+patients+%28pts%29+with+unresectable+or+hormone+receptor-positive+%28HR%2B%29%2C+HER2-neagtive+metastatic+breast+cancer+%28MBC%29%3A+MAINTAIN+trialJ%C2%A0Clin+Oncol402022LBA+1004)

[61.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref63-1 "View in article")

André, F. ∙ Ciruelos, E. ∙ Rubovszky, G. ...

**Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer**

*N Engl J Med.* 2019; **380**:1929-1940

[Crossref](https://doi.org/10.1056/NEJMoa1813904)

[Scopus (1327)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_61_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85065812556)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31091374/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1813904&pmid=31091374)

[62.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref63-1 "View in article")

André, F. ∙ Ciruelos, E.M. ∙ Juric, D. ...

**Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1**

*Ann Oncol.* 2021; **32**:208-217

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_62_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2020.11.011&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_62_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2020.11.011&cf=pdf&site=annonc-site)

[Scopus (242)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_62_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85098218091)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33246021/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.annonc.2020.11.011&pmid=33246021)

[63.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref63-1 "View in article")

Rugo, H.S. ∙ Lerebours, F. ∙ Ciruelos, E. ...

**Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study**

*Lancet Oncol.* 2021; **22**:489-498

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_63_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2821%2900034-6&cf=fulltext&site=lancet-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_63_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2821%2900034-6&cf=pdf&site=lancet-site)

[Scopus (143)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_63_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85103415098)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33794206/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2821%2900034-6&pmid=33794206)

[64.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref67 "View in article")

Baselga, J. ∙ Campone, M. ∙ Piccart, M. ...

**Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer**

*N Engl J Med.* 2012; **366**:520-529

[Crossref](https://doi.org/10.1056/NEJMoa1109653)

[Scopus (2329)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_64_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-84863078767)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/22149876/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1109653&pmid=22149876)

[65.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref67 "View in article")

Cook, M.M. ∙ Al Rabadi, L. ∙ Kaempf, A.J. ...

**Everolimus plus exemestane treatment in patients with metastatic hormone receptor-positive breast cancer previously treated with CDK4/6 inhibitor therapy**

*Oncologist.* 2021; **26**:101-106

[Crossref](https://doi.org/10.1002/onco.13609)

[Scopus (27)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_65_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85097559327)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33230905/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1002%2Fonco.13609&pmid=33230905)

[66.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref67 "View in article")

Jerusalem, G. ∙ de Boer, R.H. ∙ Hurvitz, S. ...

**Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial**

*JAMA Oncol.* 2018; **4**:1367-1374

[Crossref](https://doi.org/10.1001/jamaoncol.2018.2262)

[Scopus (64)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_66_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85051175969)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/29862411/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1001%2Fjamaoncol.2018.2262&pmid=29862411)

[67.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref67 "View in article")

Piccart, M. ∙ Hortobagyi, G.N. ∙ Campone, M. ...

**Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2**

*Ann Oncol.* 2014; **25**:2357-2362

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_67_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1093%2Fannonc%2Fmdu456&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_67_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1093%2Fannonc%2Fmdu456&cf=pdf&site=annonc-site)

[Scopus (427)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_67_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-84921807735)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/25231953/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1093%2Fannonc%2Fmdu456&pmid=25231953)

[68.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref68-1 "View in article")

Litton, J.K. ∙ Rugo, H.S. ∙ Ettl, J. ...

**Talazoparib in patients with advanced breast cancer and a germline BRCA mutation**

*N Engl J Med.* 2018; **379**:753-763

[Crossref](https://doi.org/10.1056/NEJMoa1802905)

[Scopus (1239)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_68_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85052504313)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/30110579/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1802905&pmid=30110579)

[69.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref69-1 "View in article")

Robson, M. ∙ Goessl, C. ∙ Domchek, S.

**Olaparib for metastatic germline BRCA-mutated breast cancer**

*N Engl J Med.* 2017; **377**:1792-1793

[Crossref](https://doi.org/10.1056/NEJMc1711644)

[Scopus (9)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_69_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85032719056)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/29091556/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMc1711644&pmid=29091556)

[70.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref70 "View in article")

Brufsky, A.M. ∙ Hurvitz, S. ∙ Perez, E. ...

**RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer**

*J Clin Oncol.* 2011; **29**:4286-4293

[Crossref](https://doi.org/10.1200/JCO.2010.34.1255)

[Scopus (348)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_70_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-81155123190)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/21990397/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2010.34.1255&pmid=21990397)

[71.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref71 "View in article")

Kanai, M. ∙ Kawaguchi, T. ∙ Kotaka, M. ...

**Impact of dihydropyrimidine dehydrogenase (DPD) genotype on fluoropyrimidine-related toxicity in Asian population**

*Ann Oncol.* 2020; **31**:s1359

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_71_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2020.10.294&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_71_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2020.10.294&cf=pdf&site=annonc-site)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/32652112/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.annonc.2020.10.294&pmid=32652112)

[72.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref72 "View in article")

Gennari, A. ∙ Stockler, M. ∙ Puntoni, M. ...

**Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials**

*J Clin Oncol.* 2011; **29**:2144-2149

[Crossref](https://doi.org/10.1200/JCO.2010.31.5374)

[Scopus (160)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_72_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-79957936823)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/21464403/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2010.31.5374&pmid=21464403)

[73.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref73 "View in article")

Park, Y.H. ∙ Jung, K.H. ∙ Im, S.A. ...

**Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02**

*J Clin Oncol.* 2013; **31**:1732-1739

[Crossref](https://doi.org/10.1200/JCO.2012.45.2490)

[Scopus (71)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_73_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-84879476708)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/23569309/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2012.45.2490&pmid=23569309)

[74.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref74 "View in article")

Rugo, H.S. ∙ Bardia, A. ∙ Marme, F. ...

**Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer**

*J Clin Oncol.* 2022; **40**:3365-3376

[Crossref](https://doi.org/10.1200/JCO.22.01002)

[Scopus (0)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_74_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85139572298)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/36027558/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.22.01002&pmid=36027558)

[75.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref75 "View in article")

Rugo, H.S. ∙ Bardia, A. ∙ Marme, F. ...

**Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)**

*Ann Oncol.* 2022; **33**:S1386

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_75_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2022.08.012&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_75_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2022.08.012&cf=pdf&site=annonc-site)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.annonc.2022.08.012)

[76.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref76 "View in article")

Kaklamani V, Bidard FC, Neven P, et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2-metastatic breast cancer: updated results by duration of prior CDK4/6 inhibitor in metastatic setting. Paper presented at 2022 San Antonio Breast Cancer Symposium. December 8, 2022. Abstract GS3-01.

[Google Scholar](https://scholar.google.com/scholar?q=Kaklamani+V%2C+Bidard+FC%2C+Neven+P%2C+et%C2%A0al.+EMERALD+phase+3+trial+of+elacestrant+versus+standard+of+care+endocrine+therapy+in+patients+with+ER%2B%2FHER2-metastatic+breast+cancer%3A+updated+results+by+duration+of+prior+CDK4%2F6+inhibitor+in+metastatic+setting.+Paper+presented+at+2022+San+Antonio+Breast+Cancer+Symposium.+December+8%2C+2022.+Abstract+GS3-01.)

[77.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref77 "View in article")

Baselga, J. ∙ Cortes, J. ∙ Kim, S.B. ...

**Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer**

*N Engl J Med.* 2012; **366**:109-119

[Crossref](https://doi.org/10.1056/NEJMoa1113216)

[Scopus (2012)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_77_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-84862914692)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/22149875/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1113216&pmid=22149875)

[78.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref78 "View in article")

Swain, S.M. ∙ Miles, D. ∙ Kim, S.B. ...

**Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study**

*Lancet Oncol.* 2020; **21**:519-530

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_78_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2819%2930863-0&cf=fulltext&site=lancet-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_78_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2819%2930863-0&cf=pdf&site=lancet-site)

[Scopus (391)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_78_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85082497684)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/32171426/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2819%2930863-0&pmid=32171426)

[79.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref79-1 "View in article")

Rimawi, M. ∙ Ferrero, J.M. ∙ de la Haba-Rodriguez, J. ...

**First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial**

*J Clin Oncol.* 2018; **36**:2826-2835

[Crossref](https://doi.org/10.1200/JCO.2017.76.7863)

[Scopus (134)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_79_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85054148622)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/30106636/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2017.76.7863&pmid=30106636)

[80.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref80 "View in article")

Cortés, J. ∙ Fumoleau, P. ∙ Bianchi, G.V. ...

**Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer**

*J Clin Oncol.* 2012; **30**:1594-1600

[Crossref](https://doi.org/10.1200/JCO.2011.37.4207)

[Scopus (213)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_80_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-84862894846)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/22393084/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2011.37.4207&pmid=22393084)

[81.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref81 "View in article")

Kaufman, B. ∙ Mackey, J.R. ∙ Clemens, M.R. ...

**Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study**

*J Clin Oncol.* 2009; **27**:5529-5537

[Crossref](https://doi.org/10.1200/JCO.2008.20.6847)

[Scopus (719)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_81_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-73949105921)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/19786670/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2008.20.6847&pmid=19786670)

[82.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref82 "View in article")

Yuan, Z. ∙ Huang, J.-J. ∙ Hua, X. ...

**Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: the SYSUCC-002 randomized clinical trial**

*J Clin Oncol.* 2021; **39**:1003

[Crossref](https://doi.org/10.1200/JCO.2021.39.15_suppl.1003)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2021.39.15_suppl.1003)

[83.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref83 "View in article")

Johnston, S.R.D. ∙ Hegg, R. ∙ Im, S.A. ...

**Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE**

*J Clin Oncol.* 2018; **36**:741-748

[PubMed](https://pubmed.ncbi.nlm.nih.gov/29244528/)

[Google Scholar](https://scholar.google.com/scholar_lookup?pmid=29244528)

[84.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref84 "View in article")

Johnston, S. ∙ Pippen, Jr., J. ∙ Pivot, X. ...

**Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer**

*J Clin Oncol.* 2009; **27**:5538-5546

[Crossref](https://doi.org/10.1200/JCO.2009.23.3734)

[Scopus (910)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_84_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-73149115341)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/19786658/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2009.23.3734&pmid=19786658)

[85.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref85-1 "View in article")

Cortes, J. ∙ Kim, S.B. ∙ Chung, W.P. ...

**Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer**

*N Engl J Med.* 2022; **386**:1143-1154

[Crossref](https://doi.org/10.1056/NEJMoa2115022)

[Scopus (336)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_85_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85127402448)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/35320644/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa2115022&pmid=35320644)

[86.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref86 "View in article")

Lin, N.U. ∙ Borges, V. ∙ Anders, C. ...

**Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial**

*J Clin Oncol.* 2020; **38**:2610-2619

[Crossref](https://doi.org/10.1200/JCO.20.00775)

[Scopus (281)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_86_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85086111080)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/32468955/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.20.00775&pmid=32468955)

[87.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref87-1 "View in article")

Murthy, R.K. ∙ Loi, S. ∙ Okines, A. ...

**Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer**

*N Engl J Med.* 2020; **382**:597-609

[Crossref](https://doi.org/10.1056/NEJMoa1914609)

[Scopus (694)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_87_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85077435898)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31825569/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1914609&pmid=31825569)

[88.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref88 "View in article")

Modi, S. ∙ Saura, C. ∙ Yamashita, T. ...

**Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer**

*Cancer Res.* 2021; **81**:PD3-PD06

[Google Scholar](https://scholar.google.com/scholar?q=S.ModiC.SauraT.YamashitaUpdated+results+from+DESTINY-breast01%2C+a+phase+2+trial+of+trastuzumab+deruxtecan+%28T-DXd%29+in+HER2+positive+metastatic+breast+cancerCancer+Res81suppl+42021PD3PD06)

[89.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref89 "View in article")

Verma, S. ∙ Miles, D. ∙ Gianni, L. ...

**Trastuzumab emtansine for HER2-positive advanced breast cancer**

*N Engl J Med.* 2012; **367**:1783-1791

[Crossref](https://doi.org/10.1056/NEJMoa1209124)

[Scopus (2796)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_89_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-84868520609)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/23020162/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1209124&pmid=23020162)

[90.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref94 "View in article")

Blackwell, K.L. ∙ Burstein, H.J. ∙ Storniolo, A.M. ...

**Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer**

*J Clin Oncol.* 2010; **28**:1124-1130

[Crossref](https://doi.org/10.1200/JCO.2008.21.4437)

[Scopus (796)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_90_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-77949884661)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/20124187/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2008.21.4437&pmid=20124187)

[91.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref94 "View in article")

Gui, X. ∙ Li, H. ∙ Yan, Y. ...

**Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study**

*Oncol Lett.* 2020; **20**:378

[Crossref](https://doi.org/10.3892/ol.2020.12241)

[Scopus (4)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_91_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85095876514)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33154776/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.3892%2Fol.2020.12241&pmid=33154776)

[92.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref94 "View in article")

Sudeep, G. ∙ Sanjoy, C. ∙ Jagdish, N. ...

**Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer: an Indian perspective**

*Indian J Med Paediatr Oncol.* 2018; **39**:368-379

[Crossref](https://doi.org/10.4103/ijmpo.ijmpo_201_17)

[Scopus (0)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_92_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85051852169)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.4103%2Fijmpo.ijmpo_201_17)

[93.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref94 "View in article")

Ro, J. ∙ Park, S. ∙ Kim, S. ...

**Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea**

*BMC Cancer.* 2012; **12**:322

[Crossref](https://doi.org/10.1186/1471-2407-12-322)

[Scopus (21)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_93_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-84864191059)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/22839200/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1186%2F1471-2407-12-322&pmid=22839200)

[94.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref94 "View in article")

Xu, B.H. ∙ Jiang, Z.F. ∙ Chua, D. ...

**Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients**

*Chin J Cancer.* 2011; **30**:327-335

[Crossref](https://doi.org/10.5732/cjc.010.10507)

[Scopus (32)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_94_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-79958157530)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/21527065/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.5732%2Fcjc.010.10507&pmid=21527065)

[95.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref95-1 "View in article")

Saura, C. ∙ Oliveira, M. ∙ Feng, Y.H. ...

**Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial**

*J Clin Oncol.* 2020; **38**:3138-3149

[Crossref](https://doi.org/10.1200/JCO.20.00147)

[Scopus (312)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_95_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85088803559)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/32678716/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.20.00147&pmid=32678716)

[96.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref96-1 "View in article")

Rugo, H.S. ∙ Im, S.A. ∙ Cardoso, F. ...

**Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial**

*JAMA Oncol.* 2021; **7**:573-584

[Crossref](https://doi.org/10.1001/jamaoncol.2020.7932)

[Scopus (189)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_96_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85099823030)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33480963/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1001%2Fjamaoncol.2020.7932&pmid=33480963)

[97.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref97 "View in article")

Sim, S.H. ∙ Kim, J.E. ∙ Kim, M.H. ...

**Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician’s choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)**

*Breast.* 2022; **65**:172-178

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_97_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.breast.2022.08.002&cf=fulltext&site=ybrst-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_97_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.breast.2022.08.002&cf=pdf&site=ybrst-site)

[Scopus (0)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_97_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85136302494)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/36029565/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.breast.2022.08.002&pmid=36029565)

[98.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref101 "View in article")

Lehmann, B.D. ∙ Pietenpol, J.A.

**Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes**

*J Pathol.* 2014; **232**:142-150

[Crossref](https://doi.org/10.1002/path.4280)

[Scopus (328)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_98_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-84890283025)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/24114677/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1002%2Fpath.4280&pmid=24114677)

[99.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref101 "View in article")

Yin, L. ∙ Duan, J.J. ∙ Bian, X.W. ...

**Triple-negative breast cancer molecular subtyping and treatment progress**

*Breast Cancer Res.* 2020; **22**:61

[Crossref](https://doi.org/10.1186/s13058-020-01296-5)

[Scopus (839)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_99_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85086355994)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/32517735/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1186%2Fs13058-020-01296-5&pmid=32517735)

[100.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref101 "View in article")

Lee, J.A. ∙ Kim, K.I. ∙ Bae, J.W. ...

**Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival**

*Breast Cancer Res Treat.* 2010; **123**:177-187

[Crossref](https://doi.org/10.1007/s10549-010-0998-5)

[Scopus (45)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_100_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-77955770298)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/20574671/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1007%2Fs10549-010-0998-5&pmid=20574671)

[101.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref101 "View in article")

Wang, C. ∙ Kar, S. ∙ Lai, X. ...

**Triple negative breast cancer in Asia: an insider’s view**

*Cancer Treat Rev.* 2018; **62**:29-38

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_101_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.ctrv.2017.10.014&cf=fulltext&site=yctrv-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_101_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.ctrv.2017.10.014&cf=pdf&site=yctrv-site)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/29154023/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.ctrv.2017.10.014&pmid=29154023)

[102.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref102 "View in article")

Miles, D. ∙ Gligorov, J. ∙ Andre, F. ...

**Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer**

*Ann Oncol.* 2021; **32**:994-1004

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_102_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2021.05.801&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_102_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2021.05.801&cf=pdf&site=annonc-site)

[Scopus (300)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_102_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85111080655)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/34219000/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.annonc.2021.05.801&pmid=34219000)

[103.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref103 "View in article")

Cortés, J. ∙ Cescon, D.W. ∙ Rugo, H.S. ...

**Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial**

*Lancet.* 2020; **396**:1817-1828

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_103_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS0140-6736%2820%2932531-9&cf=fulltext&site=lancet-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_103_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS0140-6736%2820%2932531-9&cf=pdf&site=lancet-site)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33278935/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0140-6736%2820%2932531-9&pmid=33278935)

[104.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref104 "View in article")

Im, S.A. ∙ Xu, B. ∙ Li, W. ...

**Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis**

*Sci Rep.* 2020; **10**:8753

[Crossref](https://doi.org/10.1038/s41598-020-63033-4)

[Scopus (20)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_104_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85085715184)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/32472001/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41598-020-63033-4&pmid=32472001)

[105.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref105 "View in article")

Lee, K.H. ∙ Sohn, J. ∙ Goodwin, A. ...

**Talazoparib versus chemotherapy in patients with HER2-negative advanced breast cancer and a germline BRCA1/2 mutation enrolled in Asian countries: exploratory subgroup analysis of the phase III EMBRACA trial**

*Cancer Res Treat.* 2021; **53**:1084-1095

[Crossref](https://doi.org/10.4143/crt.2020.1381)

[Scopus (1)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_105_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85111600834)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33781053/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.4143%2Fcrt.2020.1381&pmid=33781053)

[106.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref108 "View in article")

Tutt, A. ∙ Tovey, H. ∙ Cheang, M.C.U. ...

**Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial**

*Nat Med.* 2018; **24**:628-637

[Crossref](https://doi.org/10.1038/s41591-018-0009-7)

[Scopus (594)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_106_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85046110400)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/29713086/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41591-018-0009-7&pmid=29713086)

[107.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref108 "View in article")

Hu, X.C. ∙ Zhang, J. ∙ Xu, B.H. ...

**Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial**

*Lancet Oncol.* 2015; **16**:436-446

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_107_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2815%2970064-1&cf=fulltext&site=lancet-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_107_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2815%2970064-1&cf=pdf&site=lancet-site)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/25795409/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2815%2970064-1&pmid=25795409)

[108.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref108 "View in article")

Zhang, J. ∙ Wang, Z. ∙ Hu, X. ...

**Cisplatin and gemcitabine as the first-line therapy in metastatic triple negative breast cancer**

*Int J Cancer.* 2015; **136**:204-211

[Crossref](https://doi.org/10.1002/ijc.28966)

[Scopus (54)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_108_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-84925283516)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/24824628/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1002%2Fijc.28966&pmid=24824628)

[109.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref109 "View in article")

Piccart-Gebhart, M.J. ∙ Burzykowski, T. ∙ Buyse, M. ...

**Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer**

*J Clin Oncol.* 2008; **26**:1980-1986

[Crossref](https://doi.org/10.1200/JCO.2007.10.8399)

[Scopus (193)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_109_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-42949158252)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/18421049/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2007.10.8399&pmid=18421049)

[110.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref110 "View in article")

Yardley, D.A. ∙ Coleman, R. ∙ Conte, P. ...

**Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial**

*Ann Oncol.* 2018; **29**:1763-1770

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_110_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1093%2Fannonc%2Fmdy201&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_110_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1093%2Fannonc%2Fmdy201&cf=pdf&site=annonc-site)

[Scopus (84)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_110_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85055535644)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/29878040/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1093%2Fannonc%2Fmdy201&pmid=29878040)

[111.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref111-1 "View in article")

Bardia, A. ∙ Hurvitz, S.A. ∙ Tolaney, S.M. ...

**Sacituzumab govitecan in metastatic triple-negative breast cancer**

*N Engl J Med.* 2021; **384**:1529-1541

[Crossref](https://doi.org/10.1056/NEJMoa2028485)

[Scopus (472)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_111_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85104884390)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33882206/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa2028485&pmid=33882206)

[112.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref112-1 "View in article")

Bardia, A. ∙ Messersmith, W.A. ∙ Kio, E.A. ...

**Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial**

*Ann Oncol.* 2021; **32**:746-756

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_112_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2021.03.005&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_112_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2021.03.005&cf=pdf&site=annonc-site)

[Scopus (104)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_112_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85104855700)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33741442/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.annonc.2021.03.005&pmid=33741442)

[113.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref113 "View in article")

Modi, S. ∙ Park, H. ∙ Murthy, R.K. ...

**Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study**

*J Clin Oncol.* 2020; **38**:1887-1896

[Crossref](https://doi.org/10.1200/JCO.19.02318)

[Scopus (392)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_113_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85081268424)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/32058843/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.19.02318&pmid=32058843)

[114.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref114 "View in article")

Modi, S. ∙ Saura, C. ∙ Yamashita, T. ...

**Trastuzumab deruxtecan in previously treated HER2-positive breast cancer**

*N Engl J Med.* 2020; **382**:610-621

[Crossref](https://doi.org/10.1056/NEJMoa1914510)

[Scopus (999)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_114_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85077471546)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31825192/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1914510&pmid=31825192)

[115.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref115 "View in article")

Robson, M. ∙ Ruddy, K.J. ∙ Im, S.A. ...

**Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial**

*Eur J Cancer.* 2019; **120**:20-30

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_115_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.ejca.2019.06.023&cf=fulltext&site=ejc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_115_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.ejca.2019.06.023&cf=pdf&site=ejc-site)

[Scopus (52)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_115_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85070926015)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31446213/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.ejca.2019.06.023&pmid=31446213)

[116.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref118-1 "View in article")

Badwe, R. ∙ Hawaldar, R. ∙ Nair, N. ...

**Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial**

*Lancet Oncol.* 2015; **16**:1380-1388

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_116_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2815%2900135-7&cf=fulltext&site=lancet-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_116_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2815%2900135-7&cf=pdf&site=lancet-site)

[Scopus (377)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_116_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-84952871468)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/26363985/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2815%2900135-7&pmid=26363985)

[117.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref118-1 "View in article")

Fitzal, F. ∙ Bjelic-Radisic, V. ∙ Knauer, M. ...

**Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial**

*Ann Surg.* 2019; **269**:1163-1169

[Crossref](https://doi.org/10.1097/SLA.0000000000002771)

[Scopus (115)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_117_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85066060786)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31082916/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1097%2FSLA.0000000000002771&pmid=31082916)

[118.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref118-1 "View in article")

Soran, A. ∙ Ozmen, V. ∙ Ozbas, S. ...

**Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01**

*Ann Surg Oncol.* 2018; **25**:3141-3149

[Crossref](https://doi.org/10.1245/s10434-018-6494-6)

[Scopus (221)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_118_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85047165280)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/29777404/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1245%2Fs10434-018-6494-6&pmid=29777404)

[119.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref119 "View in article")

Khan, S.A. ∙ Zhao, F. ∙ Solin, L.J. ...

**A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the ECOG-ACRIN Research Group (2108)**

*J Clin Oncol.* 2020; **38** LBA2

[Crossref](https://doi.org/10.1200/JCO.2020.38.18_suppl.LBA2)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/32442069/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2020.38.18_suppl.LBA2&pmid=32442069)

[120.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref120 "View in article")

Le Rhun, E. ∙ Guckenberger, M. ∙ Smits, M. ...

**EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours**

*Ann Oncol.* 2021; **32**:1332-1347

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_120_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2021.07.016&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_120_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2021.07.016&cf=pdf&site=annonc-site)

[Scopus (169)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_120_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85114662933)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/34364998/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.annonc.2021.07.016&pmid=34364998)

[121.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref121 "View in article")

Harbeck, N. ∙ Franke, F. ∙ Villanueva-Vazquez, R. ...

**Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)**

*Ther Adv Med Oncol.* 2020; **12**, 1758835920943065

[Crossref](https://doi.org/10.1177/1758835920943065)

[Scopus (37)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_121_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85088639533)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1177%2F1758835920943065)

[122.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref122 "View in article")

Ciruelos, E.M. ∙ Rugo, H.S. ∙ Mayer, I.A. ...

**Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer from SOLAR-1**

*J Clin Oncol.* 2021; **39**:2005-2015

[Crossref](https://doi.org/10.1200/JCO.20.01139)

[Scopus (16)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_122_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85108386804)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33780274/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.20.01139&pmid=33780274)

[123.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref123 "View in article")

Murthy, R. ∙ Borges, V.F. ∙ Conlin, A. ...

**Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study**

*Lancet Oncol.* 2018; **19**:880-888

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_123_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2818%2930256-0&cf=fulltext&site=lancet-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_123_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2818%2930256-0&cf=pdf&site=lancet-site)

[Scopus (136)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_123_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85047241419)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/29804905/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2818%2930256-0&pmid=29804905)

[124.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref124 "View in article")

Litton, J.K. ∙ Hurvitz, S.A. ∙ Mina, L.A. ...

**Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial**

*Ann Oncol.* 2020; **31**:1526-1535

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_124_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2020.08.2098&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_124_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2020.08.2098&cf=pdf&site=annonc-site)

[Scopus (180)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_124_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85092215405)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/32828825/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.annonc.2020.08.2098&pmid=32828825)

[125.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref125-1 "View in article")

Bardia, A. ∙ Tolaney, S.M. ∙ Punie, K. ...

**Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer**

*Ann Oncol.* 2021; **32**:1148-1156

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_125_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2021.06.002&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_125_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2Fj.annonc.2021.06.002&cf=pdf&site=annonc-site)

[Scopus (116)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_125_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85109025820)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/34116144/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.annonc.2021.06.002&pmid=34116144)

[126.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref129 "View in article")

Ma, F. ∙ Ouyang, Q. ∙ Li, W. ...

**Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study**

*J Clin Oncol.* 2019; **37**:2610-2619

[Crossref](https://doi.org/10.1200/JCO.19.00108)

[Scopus (205)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_126_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85072993966)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31430226/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.19.00108&pmid=31430226)

[127.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref129 "View in article")

Anwar, M. ∙ Chen, Q. ∙ Ouyang, D. ...

**Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data**

*Clin Cancer Res.* 2021; **27**:4634-4641

[Crossref](https://doi.org/10.1158/1078-0432.CCR-21-0474)

[Scopus (21)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_127_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85113633827)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/34112711/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1158%2F1078-0432.CCR-21-0474&pmid=34112711)

[128.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref129 "View in article")

Zhang, L. ∙ Wu, X. ∙ Zhou, J. ...

**Pyrotinib in the treatment of women with HER2-positive advanced breast cancer: a multicenter, prospective, real-world study**

*Front Oncol.* 2021; **11**, 699323

[Google Scholar](https://scholar.google.com/scholar?q=L.ZhangX.WuJ.ZhouPyrotinib+in+the+treatment+of+women+with+HER2-positive+advanced+breast+cancer%3A+a+multicenter%2C+prospective%2C+real-world+studyFront+Oncol112021699323)

[129.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref129 "View in article")

Xu, B. ∙ Yan, M. ∙ Ma, F. ...

**Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial**

*Lancet Oncol.* 2021; **22**:351-360

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_129_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2820%2930702-6&cf=fulltext&site=lancet-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_129_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1016%2FS1470-2045%2820%2930702-6&cf=pdf&site=lancet-site)

[Scopus (151)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_129_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85101699848)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33581774/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2820%2930702-6&pmid=33581774)

[130.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref130 "View in article")

Xu, B. ∙ Yan, M. ∙ Ma, F. ...

**Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): a randomized phase III trial**

*Ann Oncol.* 2022; **33**:LBA19

[Google Scholar](https://scholar.google.com/scholar?q=B.XuM.YanF.MaPyrotinib+or+placebo+in+combination+with+trastuzumab+and+docetaxel+for+HER2-positive+metastatic+breast+cancer+%28PHILA%29%3A+a+randomized+phase+III+trialAnn+Oncol332022LBA19)

[131.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref131-1 "View in article")

Xu, B. ∙ Zhang, Q. ∙ Zhang, P. ...

**Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial**

*Nat Med.* 2021; **27**:1904-1909

[Crossref](https://doi.org/10.1038/s41591-021-01562-9)

[Scopus (48)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_131_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85118888923)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/34737452/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41591-021-01562-9&pmid=34737452)

[132.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref132 "View in article")

Zhang, J. ∙ Meng, Y. ∙ Wang, B. ...

**Dalpiciclib combined with pyrotinib and letrozole in women with HER2-positive, hormone receptor-positive metastatic breast cancer (LORDSHIPS): a phase Ib study**

*Front Oncol.* 2022; **12**, 775081

[Google Scholar](https://scholar.google.com/scholar?q=J.ZhangY.MengB.WangDalpiciclib+combined+with+pyrotinib+and+letrozole+in+women+with+HER2-positive%2C+hormone+receptor-positive+metastatic+breast+cancer+%28LORDSHIPS%29%3A+a+phase+Ib+studyFront+Oncol122022775081)

[133.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#fig1 "View in article")

Mateo, J. ∙ Chakravarty, D. ∙ Dienstmann, R. ...

**A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)**

*Ann Oncol.* 2018; **29**:1895-1902

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_133_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1093%2Fannonc%2Fmdy263&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_133_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1093%2Fannonc%2Fmdy263&cf=pdf&site=annonc-site)

[Scopus (346)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_133_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85054325308)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/30137196/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1093%2Fannonc%2Fmdy263&pmid=30137196)

[134.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#fig2 "View in article")

Cherny, N.I. ∙ Dafni, U. ∙ Bogaerts, J. ...

**ESMO-Magnitude of Clinical Benefit Scale version 1.1**

*Ann Oncol.* 2017; **28**:2340-2366

[Full Text](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_134_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1093%2Fannonc%2Fmdx310&cf=fulltext&site=annonc-site)

[Full Text (PDF)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_134_2&dbid=4&doi=10.1016%2Fj.esmoop.2023.101541&key=10.1093%2Fannonc%2Fmdx310&cf=pdf&site=annonc-site)

[Scopus (393)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_134_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85030556510)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/28945867/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1093%2Fannonc%2Fmdx310&pmid=28945867)

[135.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref137 "View in article")

Li, C. ∙ Bian, X. ∙ Liu, Z. ...

**Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: a real-world retrospective study**

*Cancer Med.* 2021; **10**:8352-8364

[Crossref](https://doi.org/10.1002/cam4.4335)

[Scopus (9)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_135_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85117407241)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/34672424/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1002%2Fcam4.4335&pmid=34672424)

[136.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref137 "View in article")

Li, F. ∙ Xu, F. ∙ Li, J. ...

**Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study**

*Ann Transl Med.* 2021; **9**:103

[Crossref](https://doi.org/10.21037/atm-20-4054)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/33569405/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.21037%2Fatm-20-4054&pmid=33569405)

[137.](https://www.esmoopen.com/article/S2059-7029(23)00767-6/fulltext#body-ref-sref137 "View in article")

Ma, X. ∙ Li, Y. ∙ Li, L. ...

**Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases**

*Ann Med.* 2022; **54**:3085-3095

[Crossref](https://doi.org/10.1080/07853890.2022.2139411)

[Scopus (1)](https://www.esmoopen.com/servlet/linkout?suffix=e_1_5_1_2_137_2&dbid=137438953472&doi=10.1016%2Fj.esmoop.2023.101541&key=2-s2.0-85141678727)

[PubMed](https://pubmed.ncbi.nlm.nih.gov/36331291/)

[Google Scholar](https://scholar.google.com/scholar_lookup?doi=10.1080%2F07853890.2022.2139411&pmid=36331291)